Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other ...
Dec 9, 2012
0
0
More precise dosing methods and cellular engineering techniques show promise in the effort to improve treatment of aggressive cancers with personalized cellular therapies, according to new studies from researchers in the ...
Jun 3, 2016
0
3
Researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases in Vienna, the University Medical Center of Regensburg, ...
Jan 29, 2020
0
3
(HealthDay)—A new combination of drugs might prolong life in certain older leukemia patients, a new study suggests.
Jan 9, 2014
0
0
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center—Arthur ...
Jul 21, 2021
0
1
(HealthDay)—Venclexta (venetoclax) has been approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL) characterized by a specific chromosomal abnormality called the 17p deletion.
Apr 11, 2016
0
0
Patients with advanced chronic lymphocytic leukemia (CLL) often receive donor transplants that effectively "reboot" their own immune defenses, which then attack and potentially cure the hard-to-treat disease. However, there ...
Aug 5, 2013
0
0
Treating B cell malignancies with the patients' own T cells modified so as to target specific B cell markers has shown clinical success.
Jun 6, 2016
0
1
The latest results of clinical trials of more than 125 patients testing an investigational personalized cellular therapy known as CTL019 will be presented by a University of Pennsylvania research team at the 56th American ...
Dec 8, 2014
0
0
Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the ...
Dec 10, 2012
0
0
